What cancers does dotalizumab (Jemperli) treat?

Dotalizumab (Jemperli) is primarily used to treat ovarian cancers with highly unstable microsatellite mismatches (dMMR) or deficient DNA mismatch repair (dMMR). This type of ovarian cancer has a lot of DNA damage and mutations, making it easier for the immune system to recognize and attack the cancer cells. Therefore, dotalizumab provides a new treatment option for patients with these specific types of ovarian cancer.

Currently, the approved indications for dotalizumab are limited to patients with ovarian cancer who have a highly unstable microsatellite mismatch (dMMR) or who lack DNA mismatch repair (dMMR). It is not used to treat other types of cancer. Dotalizumab provides a promising treatment option for these specific patients by inhibiting signaling pathways at the PD-1 (programmed death 1) receptor, enhancing the immune system's attack on cancer cells.

Please note that the medical field is constantly evolving and the indications for immunotherapy drugs may expand as new research and clinical trials are conducted. Therefore, if you or someone you know has cancer, especially ovarian cancer, and is interested in dotalizumab or other treatments, it is recommended that you consult a medical professional for the latest treatment advice and information. Doctors will be able to develop the most appropriate treatment plan based on the patient's specific situation and the latest clinical guidelines.

Dotalizumab is not currently on the market in China, and it is not included in medical insurance. Patients cannot purchase it domestically and need to purchase dotalizumab through overseas channels. There are only original drugs available abroad, mainly from the United States, and the price is as high as about 50,000 yuan.